About this trial
Acute respiratory failure (ARF) is a frequent medical emergency, involving high costs for health organizations and patients who often require intensive care and respiratory assistance. According to an international study, 61% of hypoxemic patients in intensive care receive invasive ventilation \[3\]. Invasive mechanical ventilation is often unavailable in low-income countries and non-invasive ventilatory supports such as continuous positive airway pressure (CPAP) and high-flow oxygen therapy (HFO) were very useful during the COVID-19 pandemic. They reduced the rate of intubation and ICU admissions. In addition, CPAP can be used without a ventilator, no electricity is required. So, it could be a support of choice in low-income countries.
Used of Boussignac-type CPAP could potentially reduce the recourse to intubation in patients with acute hypoxemic respiratory failure in a context where access to invasive ventilation remains very limited.
Eligibility criteria
Qualifiers
Acute respiratory distress, defined as dyspnea respiratory rate ≥ 25 cycles/min
Hypoxemia, defined as the need for more 6 liters of oxygen to maintain an oxygen saturation (SpO2) of ≥ 92%. The fraction of inspired oxygen (FiO2) will be estimated using the 3% rule.
Disqualifiers
Pregnant or breastfeeding women
Persons deprived of their liberty
Exacerbation of asthma, chronic obstructive pulmonary disease, or another chronic respiratory disease
Moderate to large amount of unilateral or bilateral undrained pleural effusion
Trial design
Treatments tested in this trial
- CPAP
Treatment groups
Sponsors and collaborators
Université NAZI BONI
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborator